Skip to main content
. 2014 Aug 29;5(19):8947–8958. doi: 10.18632/oncotarget.2407

Figure 6. Extended treatment with plerixafor modulates surface expression of surface CXCR4 and affects SDF-1α-induced chemotaxis.

Figure 6

Cell lines were treated with plerixafor (10 nM, 100 nM) or vehicle control (0 nM) for 72 hours and analyzed by flow cytometry and chemotaxis assays. Surface expression of CXCR4 using 12G5, 1D9, and 2B11 antibodies in (A) Nalm-6 and (B) HB-1119. Cells were then washed and resuspended in fresh medium. Chemotaxis toward medium with or without recombinant SDF-1α (150 ng/mL) after 24 hours in (C) Nalm-6 and (D) HB-1119. In separate experiments, Nalm-6 and HB-1119 were treated with plerixafor or vehicle control for 72 hours and cells were harvested at multiple time points for flow cytometry and chemotaxis. Surface expression of CXCR4 measured at multiple time points using 12G5, 1D9, and 2B11 antibodies in (E) Nalm-6 and (F) HB-1119. Cells treated with plerixafor or vehicle control for 4 hours were washed and resuspended in fresh medium. Chemotaxis toward medium with or without recombinant SDF-1α (150 ng/mL) after 1 hour in (G) Nalm-6 and (H) HB-1119, after 24 hours in (I) Nalm-6 and (J) HB-1119. *p<0.05, **p<0.01, ***p<0.001 vs. 0+SDF.